Comparison of procedure-related complications between percutaneous cryoablation and radiofrequency ablation for treating periductal hepatocellular carcinoma

References

• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–853.
   PubMed Web of Science ®Google Scholar
• Gervais DA, Goldberg SN, Brown DB, et al. Society of Interventional Radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc Interv Radiol. 2009;20(7 Suppl):S342–S347.
   PubMed Web of Science ®Google Scholar
• Kasugai H, Osaki Y, Oka H, Osaka Liver Cancer Study Group, et al. Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients. Oncology. 2007;72(Suppl 1):72–75.
   PubMed Web of Science ®Google Scholar
• Koda M, Murawaki Y, Hirooka Y, et al. Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: an analysis of 16 346 treated nodules in 13 283 patients. Hepatol Res. 2012;42(11):1058–1064.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang H, Yang W, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology. 2015;61(5):1579–1590.
   PubMed Web of Science ®Google Scholar
• Dunne RM, Shyn PB, Sung JC, et al. Percutaneous treatment of hepatocellular carcinoma in patients with cirrhosis: a comparison of the safety of cryoablation and radiofrequency ablation. Eur J Radiol. 2014;83(4):632–638.
   PubMed Web of Science ®Google Scholar
• Song KD. Percutaneous cryoablation for hepatocellular carcinoma. Clin Mol Hepatol. 2016;22(4):509–515.
   PubMed Web of Science ®Google Scholar
• Kim GM, Won JY, Kim MD, et al. Cryoablation of hepatocellular carcinoma with high-risk for percutaneous ablation: safety and efficacy. Cardiovasc Intervent Radiol. 2016;39(10):1447–1454.
   PubMed Web of Science ®Google Scholar
• Fairchild AH, Tatli S, Dunne RM, et al. Percutaneous cryoablation of hepatic tumors adjacent to the gallbladder: assessment of safety and effectiveness. J Vasc Interv Radiol. 2014;25(9):1449–1455.
   PubMed Web of Science ®Google Scholar
• Kim R, Kang TW, Cha DI, et al. Percutaneous cryoablation for perivascular hepatocellular carcinoma: therapeutic efficacy and vascular complications. Eur Radiol. 2019;29(2):654–662.
   PubMed Web of Science ®Google Scholar
• Raman SS, Aziz D, Chang X, et al. Minimizing central bile duct injury during radiofrequency ablation: use of intraductal chilled saline perfusion–initial observations from a study in pigs. Radiology. 2004;232(1):154–159.
   PubMed Web of Science ®Google Scholar
• Lin MX, Ye JY, Tian WS, et al. Risk factors for bile duct injury after percutaneous thermal ablation of malignant liver tumors: a retrospective case-control study. Dig Dis Sci. 2017;62(4):1086–1094.
   PubMed Web of Science ®Google Scholar
• Liu J, Wu Y, Xu E, et al. Risk factors of intrahepatic biloma and secondary infection after thermal ablation for malignant hepatic tumors. Int J Hyperthermia. 2019;36(1):980–985.
   PubMed Web of Science ®Google Scholar
• Kondo Y, Shiina S, Tateishi R, et al. Intrahepatic bile duct dilatation after percutaneous radiofrequency ablation for hepatocellular carcinoma: impact on patient's prognosis. Liver Int. 2011;31(2):197–205.
   PubMed Web of Science ®Google Scholar
• Littrup PJ, Aoun HD, Adam B, et al. Percutaneous cryoablation of hepatic tumors: long-term experience of a large U.S. series. Abdom Radiol. 2016;41(4):767–780.
   PubMed Web of Science ®Google Scholar
• Kang TW, Lim HK, Lee MW, et al. Aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation: risk factors and clinical significance. Radiology. 2015;276(1):274–285.
   PubMed Web of Science ®Google Scholar
• Korean Liver Cancer Study G, National Cancer Center K. 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol. 2015;16(3):465–522.
   PubMed Web of Science ®Google Scholar
• Lee MW. Fusion imaging of real-time ultrasonography with CT or MRI for hepatic intervention. Ultrasonography. 2014;33(4):227–239.
   PubMedGoogle Scholar
• Song KD, Lee MW, Rhim H, et al. Percutaneous US/MRI fusion-guided radiofrequency ablation for recurrent subcentimeter hepatocellular carcinoma: technical feasibility and therapeutic outcomes. Radiology. 2018;288(3):878–886.
   PubMed Web of Science ®Google Scholar
• Chang W, Lee JM, Lee DH, et al. Comparison of switching bipolar ablation with multiple cooled wet electrodes and switching monopolar ablation with separable clustered electrode in treatment of small hepatocellular carcinoma: a randomized controlled trial. PLoS One. 2018;13(2):e0192173.
   PubMed Web of Science ®Google Scholar
• Lee JM, Han JK, Kim HC, et al. Multiple-electrode radiofrequency ablation of in vivo porcine liver: comparative studies of consecutive monopolar, switching monopolar versus multipolar modes. Invest Radiol. 2007;42(10):676–683.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Solbiati L, Brace CL, Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria-a 10-year update. Radiology. 2014;273(1):241–260.
   PubMed Web of Science ®Google Scholar
• Ge N, Huang J, Shi Z, et al. Safety and efficacy of microwave ablation for periductal hepatocellular carcinoma with intraductal cooling of the central bile ducts through a percutaneous transhepatic cholangial drainage tube. J Interv Med. 2019;2(2):84–90.
   PubMedGoogle Scholar
• European Association for the Study of the Liver. Electronic address [email protected], European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Cha DI, Lee MW, Rhim H, et al. Therapeutic efficacy and safety of percutaneous ethanol injection with or without combined radiofrequency ablation for hepatocellular carcinomas in high risk locations. Korean J Radiol. 2013;14(2):240–247.
   PubMed Web of Science ®Google Scholar
• Silk MT, Wimmer T, Lee KS, et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Interv Radiol. 2014;25(1):112–118.
   PubMed Web of Science ®Google Scholar
• Dollinger M, Zeman F, Niessen C, et al. Bile duct injury after irreversible electroporation of hepatic malignancies: evaluation of MR imaging findings and laboratory values. J Vasc Interv Radiol. 2016;27(1):96–103.
   PubMed Web of Science ®Google Scholar
• Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality—clinical implications. Technol Cancer Res Treat. 2007;6(1):37–48.
   PubMed Web of Science ®Google Scholar
• Sohn RL, Carlin AM, Steffes C, et al. The extent of cryosurgery increases the complication rate after hepatic cryoablation. Am Surg. 2003;69(4):317–323.
   PubMed Web of Science ®Google Scholar
• Cha SY, Kang TW, Min JH, et al. RF ablation versus cryoablation for small perivascular hepatocellular carcinoma: propensity score analyses of mid-term outcomes. Cardiovasc Intervent Radiol. 2020;43(3):434–444.
   PubMed Web of Science ®Google Scholar